(Q71321849)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

title

A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

1 reference

R S Witte

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

T Leong

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

M S Ernstoff

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

R L Krigel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

M M Oken

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

J Harris

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

D C Tormey

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

D L Trump

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

publication date

1 January 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

17 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

page(s)

241-247

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00873807

17 October 2019

exact match

0 references

cites work

Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma

1 reference

12 December 2020

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience.

1 reference

12 December 2020

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

1 reference

12 December 2020

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Immunotherapy for metastatic renal cell carcinoma

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

12 December 2020

Cancer statistics, 1993

1 reference

12 December 2020

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

12 December 2020

Cytokines and cytotoxic agents in renal cell carcinoma: a review

1 reference

12 December 2020

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

12 December 2020

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma

1 reference

12 December 2020

The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies

1 reference

12 December 2020

Partial purification and molecular characterization of a lymphokine (costimulator) required for the mitogenic response of mouse thymocytes in vitro

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873807

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8729953%20AND%20SRC:MED&resulttype=core&format=json

17 October 2019

1 reference